3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
14
Other hematologic neoplasm
12
Plasma cell
8
Thoracic
6
Gastrointestinal
3
Gynecologic
2
Tumor-Agnostic
1
Myeloid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Interventions
Docetaxel
390
pembrolizumab
326
Prednisone
285
Gemcitabine
273
enzalutamide
256
Radiotherapy
251
Nivolumab
248
Magnetic Resonance Spectroscopy
247
Cisplatin
209
Abiraterone Acetate
198
Radiosurgery
184
Leuprolide
182
Sunitinib
169
Carboplatin
161
bicalutamide
148
Goserelin
145
Androgen Antagonists
142
Specimen Handling
138
Ipilimumab
128
Paclitaxel
125
Cyclophosphamide
116
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
110
Bevacizumab
109
Everolimus
107
apalutamide
99
abiraterone
99
cabozantinib
98
atezolizumab
97
Sorafenib
97
Radiation
89
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Maintenance
×
Genitourinary
×
Clear all
NCT07207824
2025-10-06
HERO
Fudan University
Phase 3
Not yet recruiting
182 enrolled